Sphingosine-1-phosphate

Sphingosine-1-phosphate
Skeletal formula of sphingosine-1-phosphate
Space-filling model of the sphingosine-1-phosphate anion
Identifiers
26993-30-6 N
ChEBI CHEBI:37550 YesY
ChEMBL ChEMBL225155 YesY
ChemSpider 4446673 YesY
911
Jmol 3D model Interactive image
KEGG C06124 YesY
MeSH sphingosine+1-phosphate
PubChem 5283560
Properties
C18H38NO5P
Molar mass 379.472
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

Sphingosine-1-phosphate (S1P) is a signaling sphingolipid, also known as lysosphingolipid. It is also referred to as a bioactive lipid mediator. It was discovered by Sarah Spiegel, then a professor of biochemistry and molecular biology at Georgetown University School of Medicine, in the mid-1990s.[1] Sphingolipids at large form a class of lipids characterized by a particular aliphatic aminoalcohol, which is sphingosine.

Production

Sphingosine can be released from ceramides, a process catalyzed by the enzyme ceramidase. Phosphorylation of sphingosine is catalyzed by sphingosine kinase, an enzyme ubiquitously found in the cytosol and endoplasmatic reticulum of various types of cells. S1P can be dephosphorylated to sphingosine by sphingosine phosphatases and can be irreversibly degraded by an enzyme, Sphingosine phosphate lyase.

Function

S1P is a blood borne lipid mediator, in particular in association with lipoproteins such as high density lipoprotein (HDL).[2] It is less abundant in tissue fluids. This is referred to as the S1P gradient, which seems to have biological significance in immune cell trafficking.

Originally thought as an intracellular second messenger, it was discovered to be an extracellular ligand for G protein-coupled receptor S1PR1 in 1998. It is now known that S1P receptors are members of the lysophospholipid receptor family. There are five described to date. Most of the biological effects of S1P are mediated by signaling through the cell surface receptors.

Although S1P is of importance in the entire human body, it is a major regulator of vascular and immune systems. In addition, it might be relevant in the skin. In the vascular system, S1P regulates angiogenesis, vascular stability, and permeability. In the immune system, it is now recognized as a major regulator of trafficking of T- and B-cells. S1P interaction with its receptor S1PR1 is needed for the egress of immune cells from the lymphoid organs (such as thymus and lymph nodes) into the lymphatic vessels. Inhibition of S1P receptors was shown to be critical for immunomodulation. S1P has also been shown to directly suppress TLR mediated immune response from T cells.[3]

Clinical significance

The levels of S1P ( in a range of 5-40 µmol/L ) are 5 to 10 times up-regulated in ovarian cancer patients' ascites. S1P at this physiological concentration stimulates migration and invasion of epithelial ovarian cancer cells but inhibits migration of normal ovarian surface epithelial cells.[4] Most (more than 90%) ovarian cancers arise from the epithelium of the ovary. Therefore, extracellular S1P could have an important role in cancer progression by promoting migration of epithelial ovarian cancer cells.

Administration of S1P has been shown to protect oocytes from chemotherapeutic agents in vitro,[5][6][7] as well as in vivo from chemotherapeutic and radiation therapies.[5][8][9][10] which otherwise induce apoptosis of the cells. S1P has protected ovarian tissue xenografts in SCID mouse models from radiation induced atresia.[10] In animal models these protected oocytes have been used to produce healthy live young.[8][11] Radiotherapies and chemotherapies can cause apoptosis of ovarian follicles, causing premature ovarian failure,[12] and so S1P is of great interest in fertility preservation.[13] However, its mechanism of inhibiting the sphingomyelin apoptotic pathway may also interfere with the apoptosis action of chemotherapy drugs.[14]

Ozonization of human blood is associated with increased concentrations of S1P in the plasma.[15]

The drug fingolimod (FTY720), which agonizes the S1P receptor,[16] prevents autoimmune lymphocytes from moving from the lymphoid organs into the central nervous system. It has been shown in phase III clinical trials to reduce relapses and improve other outcomes in multiple sclerosis.[17][18] S1P, as well as FTY720, has been shown to have anti-inflammatory properties at low concentrations and prevent monocyte:endothelial interactions in aorta, possibly through the S1P1 receptor.[19][20]

In addition, S1P modulates the proliferation of skin cells. This in particular applies to keratinocytes[21] while fibroblasts are not addressed in this way, apart from cell growth and differentiation While S1P suppresses epidermal proliferation as the glucocorticoids do, it differs from them in so far, as proliferation of dermal fibroblasts is not reduced. In fact, S1P even activates fibroblast-derived extracellular matrix protein production. Due to the hyperproliferative action against epidermal cells, S1P has been considered as an active pharmaceutical ingredient for hyperproliferative skin diseases, in particular, psoriasis vulgaris and acne vulgaris.

Although S1P is active at very low concentrations, bioavailability of the compound in human skin is a concern. Therefore, a topical formulation based on specific drug carriers has been considered inevitable.

ONO-4641 (a drug of Ono Pharmaceutical Co., Ltd.) is a sphingosine-1-phosphate (S1P) receptor agonist which keeps lymphocytes in lymph nodes and thereby inhibits the infiltration of lymphocytes into lesions. The compound is therefore expected to be a drug for the treatment of auto-immune diseases such as multiple sclerosis, which is regarded as an intractable disease.

Lpath Inc has produced and optimized a monoclonal anti-S1P antibody (Sphingomab). Sphingomab can absorb S1P from the extracellular fluid, thereby lowering the effective concentration of S1P. The ocular formulation of humanized Sphingomab is called ISONEP, while the systemic formulation is known as ASONEP.

See also

Notes

  1. ↑ "Massey researcher provides expert commentary on enzyme's role in cancer and inflammation". Virginia Commonwealth University. 17 May 2013. Retrieved 2 September 2015.
  2. ↑ Sattler K, Levkau B (May 2009). "Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection". Cardiovascular Research 82 (2): 201–11. doi:10.1093/cvr/cvp070. PMID 19233866.
  3. ↑ Sharma, N; et al. (2013). "Sphingosine-1-phosphate suppresses TLR-induced CXCL8 secretion from human T cells.". J Leukoc Biol 93 (4): 521–528. doi:10.1189/jlb.0712328. PMID 23345392.
  4. ↑ Wang, D; et al. (2008). "S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells.". Mol Cancer Ther 7 (7): 1993–2002. doi:10.1158/1535-7163.MCT-08-0088. PMC 2649755. PMID 18645009.
  5. 1 2 Morita Y, Perez GI, Paris F, et al. (October 2000). "Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy". Nature Medicine 6 (10): 1109–14. doi:10.1038/80442. PMID 11017141.
  6. ↑ Jurisicova A, Lee HJ, D'Estaing SG, Tilly J, Perez GI (September 2006). "Molecular requirements for doxorubicin-mediated death in murine oocytes". Cell Death and Differentiation 13 (9): 1466–74. doi:10.1038/sj.cdd.4401819. PMID 16439991.
  7. ↑ Perez, Gloria I.; Knudson, C. Michael; Leykin, Lucy; Korsmeyer, Stanley J.; Tilly, Jonathan L. (1 November 1997). "Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction". Nature Medicine 3 (11): 1228–1232. doi:10.1038/nm1197-1228.
  8. 1 2 Paris F, Perez GI, Fuks Z, et al. (September 2002). "Sphingosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring". Nature Medicine 8 (9): 901–2. doi:10.1038/nm0902-901. PMID 12205432.
  9. ↑ Kaya H, Desdicioglu R, Sezik M, et al. (March 2008). "Does sphingosine-1-phosphate have a protective effect on cyclophosphamide- and irradiation-induced ovarian damage in the rat model?". Fertility and Sterility 89 (3): 732–5. doi:10.1016/j.fertnstert.2007.03.065. PMID 17517398.
  10. 1 2 Zelinski MB, Murphy MK, Lawson MS, et al. (March 2011). "In vivo delivery of FTY720 prevents radiation-induced ovarian failure and infertility in adult female nonhuman primates". Fertility and Sterility 95 (4): 1440–5.e1–7. doi:10.1016/j.fertnstert.2011.01.012. PMC 3063448. PMID 21316047.
  11. ↑ Hancke K, Strauch O, Kissel C, Göbel H, Schäfer W, Denschlag D (January 2007). "Sphingosine 1-phosphate protects ovaries from chemotherapy-induced damage in vivo". Fertility and Sterility 87 (1): 172–7. doi:10.1016/j.fertnstert.2006.06.020. PMID 17081530.
  12. ↑ Byrne J, Fears TR, Gail MH, et al. (March 1992). "Early menopause in long-term survivors of cancer during adolescence". American Journal of Obstetrics and Gynecology 166 (3): 788–93. doi:10.1016/0002-9378(92)91335-8. PMID 1550144.
  13. ↑ Blumenfeld, Zeev (1 September 2012). "Preservation of ovarian function and fertility despite gonadotoxic chemotherapy". Expert Review of Endocrinology & Metabolism 7 (5): 567–576. doi:10.1586/eem.12.40.
  14. ↑ Roness, H.; Kalich-Philosoph, L.; Meirow, D. (2014). "Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents". Human Reproduction Update 20 (5): 759–774. doi:10.1093/humupd/dmu019. ISSN 1355-4786. PMID 24833728.
  15. ↑ Boczkowska-Radziwon, B; Chabowska, AM; Blachnio-Zabielska, A; Lukaszuk, B; Lipska, A; Chabowski, A; Radziwon, P (April 2015). "Ozonation of human blood increases sphingosine-1-phosphate in plasma.". Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 66 (2): 267–72. PMID 25903957.
  16. ↑ Baumrucker, T; et al. (2007). "FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.". Expert Opin Investig Drugs 16 (3): 283–289. doi:10.1517/13543784.16.3.283. PMID 17302523.
  17. ↑ Kappos L, Radue EW, O'Connor P, et al. (February 2010). "A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis". The New England Journal of Medicine 362 (5): 387–401. doi:10.1056/NEJMoa0909494. PMID 20089952.
  18. ↑ Cohen JA, Barkhof F, Comi G, et al. (February 2010). "Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis". The New England Journal of Medicine 362 (5): 402–15. doi:10.1056/NEJMoa0907839. PMID 20089954.
  19. ↑ Bolick DT, Srinivasan S, Kim KW, et al. (May 2005). "Sphingosine-1-Phosphate Prevents Tumor Necrosis Factor-α–Mediated Monocyte Adhesion to Aortic Endothelium in Mice". Arteriosclerosis, Thrombosis, and Vascular Biology 25 (5): 976–81. doi:10.1161/01.ATV.0000162171.30089.f6. PMID 15761190.
  20. ↑ Whetzel AM, Bolick DT, Srinivasan S, et al. (September 2006). "Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor". Circulation Research 99 (7): 731–9. doi:10.1161/01.RES.0000244088.33375.52. PMID 16960101.
  21. ↑ Manggau M, Kim DS, Ruwisch L, et al. (November 2001). "1Alpha,25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate". The Journal of Investigative Dermatology 117 (5): 1241–9. doi:10.1046/j.0022-202x.2001.01496.x. PMID 11710939.

References

This article is issued from Wikipedia - version of the Monday, April 25, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.